TAIMED BIOLOGICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83 TWD | +0.61% |
|
-0.12% | +1.22% |
| Sales 2024 * | 2.25B 68.92M 5.51B | Sales 2025 * | 1.95B 59.82M 4.78B | Capitalization | 21B 645M 51.55B |
|---|---|---|---|---|---|
| Net income 2024 * | 630M 19.34M 1.55B | Net income 2025 * | 960M 29.47M 2.36B | EV / Sales 2024 * | 8.99 x |
| Net cash position 2024 * | 824M 25.29M 2.02B | Net cash position 2025 * | 1.79B 54.85M 4.39B | EV / Sales 2025 * | 9.86 x |
| P/E ratio 2024 * |
33.8
x | P/E ratio 2025 * |
21.8
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.84% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.61% | ||
| 1 week | -0.12% | ||
| Current month | -5.14% | ||
| 1 month | -5.79% | ||
| 3 months | -4.60% | ||
| 6 months | -1.19% | ||
| Current year | +1.22% |
1 week
81.70
85.00
1 month
81.7097.70
Current year
81.70116.50
1 year
76.30135.00
3 years
52.20135.00
5 years
52.20172.50
10 years
1.05349.50
| Managers | Title | Age | Since |
|---|---|---|---|
Chin-Ming Chang
CEO | Chief Executive Officer | - | - |
I Cheng Chen
DFI | Director of Finance/CFO | - | 31/05/08 |
Nien Yuan Chang
CHM | Chairman | - | 11/06/09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chi-Chuan Chen
BRD | Director/Board Member | 66 | - |
Ta Meng Tseng
BRD | Director/Board Member | 66 | 06/09/18 |
Nien Yuan Chang
CHM | Chairman | - | 11/06/09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.11% | 2 M€ | -.--% | ||
| 0.04% | 7 M€ | -.--% | - | |
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 83 | +0.61% | 500,864 |
| 25/04/24 | 82.5 | -2.71% | 757,377 |
| 24/04/24 | 84.8 | +2.42% | 720,215 |
| 23/04/24 | 82.8 | +1.22% | 954,414 |
| 22/04/24 | 81.8 | -1.56% | 1,481,901 |
End-of-day quote Taipei Exchange, April 25, 2024
More quotes
TaiMed Biologics Inc. is a Taiwan-based company principally engaged in the research and development of new medicines. The Company mainly provides ibalizumab (TMB-355) and TMB-360, which are applied in the treatment of acquired immune deficiency syndrome (AIDS), and protease inhibitor (TMB-607), which is applied as pro-drugs for AIDS. The Company's ibalizumab is a humanized monoclonal antibody, which can interfere with the penetration of the virus into the cell. Its protease inhibitor uses nanotechnology formulation for subcutaneous and/or intramuscular injections.
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
83
TWD
Average target price
133.7
TWD
Spread / Average Target
+61.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.22% | 644M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 4147 Stock
